IBRX · TickerCove

IBRXImmunityBio, Inc.Healthcare · Biotechnologyas of 2026-09-25

Horizon

Issued 2026-09-25 at $8.44 · now $8.44 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, IBRX has typically landed between $5.65 and $13.91 — a range of −33.1% to +64.8% from the issuance price $8.44.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

2,786 overlapping 1 month windows · 2015-07-28 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($8.44) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$8.44 · 68% of range

$1.98 low$11.55 high

Trailing 52 weeks to 2026-09-25 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,391 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.7%

90% CI 51.5%–55.9%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−2.1%

typical move · IQR 28.9%

−33.1%worst (p90)+64.8%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where IBRX has typically landed a month from the 2026-09-25 close of $8.44 — the range is history, not a prediction.

now $8.44 (+0.0%)
typical $8.26 (-2.1%)
middle 50% $7.04–$9.48
90% range $5.65–$13.91

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,786 windows spanning 2015-07-28 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2023-02-08	−64.9%	−64.9%	+0.0%
2023-02-07	−64.8%	−64.8%	+0.0%
2023-02-10	−63.1%	−63.1%	+0.0%
3 best
2023-04-11	+303.9%	−0.6%	+316.2%
2023-04-06	+290.9%	−6.7%	+290.9%
2023-04-10	+274.7%	−3.2%	+305.7%

2,786 overlapping windows · 2015-07-28 – 2026-09-25 · not cherry-picked

Pending catalysts

2026-09-30 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (source, as of 2026-08-14)
October 2026 — Trial primary completion: Phase 2 primary completion: A Study to Assess Anktiva in Patients With Long Covid-19. (source, as of 2026-08-14)
May 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (source, as of 2026-08-14)
2027-05-25 — Trial primary completion: Phase 2 primary completion: Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (source, as of 2026-08-14)
February 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG (source, as of 2026-08-14)
September 2028 — Trial primary completion: Phase 3 primary completion: Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In (source, as of 2026-08-14)
2029-08-31 — Trial primary completion: Phase 2 primary completion: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (source, as of 2026-08-14)
2029-12-31 — Trial primary completion: Phase 2 primary completion: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

36%

+21.9%

n=11

Feb

55%

+7.6%

n=11

Mar

27%

−9.6%

n=11

Apr

45%

+1.3%

n=11

May

45%

+5.5%

n=11

Jun

36%

+13.5%

n=11

Jul

36%

−4.3%

n=11

Aug

33%

−9.2%

n=12

Sep

42%

−2.5%

n=12

Oct

45%

+3.0%

n=11

Nov

64%

+12.2%

n=11

Dec

36%

+4.9%

n=11

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-07-02	Cohen Cheryl	director	Sale	131,210 @ $9.50	$1.2M	−51.1% of holding	−26.0%	not yet — horizon still open	125,386	Form 4 · filed 4 days after the trade
2026-07-01	Selecky Christobel	director	Sale	159,478 @ $9.02	$1.4M	−100.0% of holding	−22.2%	not yet — horizon still open	0	Form 4 · filed 5 days after the trade
2026-06-30	Selecky Christobel	director	Sale	1,000 @ $9.00	$9K	−100.0% of holding	−14.3%	not yet — horizon still open	0	Form 4 · filed 1 day after the trade
2026-06-29	Selecky Christobel	director	Sale	95,722 @ $9.01	$862K	−100.0% of holding	−20.6%	not yet — horizon still open	0	Form 4 · filed 2 days after the trade
2026-06-24	Simon Barry J.	director	Sale	25,000 @ $7.88	$197K	−0.9% of holding	−9.8%	not yet — horizon still open	2,802,788	Form 4 · filed 2 days after the trade
2026-06-04	Simon Barry J.	director	Sale	23,033 @ $7.18	$165K	−0.8% of holding	+21.1%	not yet — horizon still open	2,827,788	Form 4 · filed 1 day after the trade
2026-02-24	Simon Barry J.	director	Sale	75,000 @ $12.01	$901K	−2.6% of holding	−25.9%	−41.1%	2,850,821	Form 4 · filed 2 days after the trade
2026-02-23	Simon Barry J.	director	Sale	165,000 @ $10.25	$1.7M	−5.3% of holding	−20.5%	−35.4%	2,925,821	Form 4 · filed 1 day after the trade
2026-02-23	Selecky Christobel	director	Sale	25,000 @ $10.00	$250K	−100.0% of holding	−20.5%	−35.4%	0	Form 4 · filed 1 day after the trade
2026-02-20	Simon Barry J.	director	Sale	10,000 @ $9.25	$93K	−0.3% of holding	+12.7%	−22.1%	3,081,604	Form 4 · filed 4 days after the trade
2026-01-20	Simon Barry J.	director	Sale	75,000 @ $7.88	$591K	−2.4% of holding	+31.9%	+5.0%	3,091,604	Form 4 · filed 1 day after the trade
2026-01-20	Simon Barry J.	director	Sale	76,967 @ $6.54	$503K	−2.4% of holding	+31.9%	+5.0%	3,166,604	Form 4 · filed 1 day after the trade
2026-01-20	Selecky Christobel	director	Sale	25,000 @ $7.51	$188K	−100.0% of holding	+31.9%	+5.0%	0	Form 4 · filed 1 day after the trade
2026-01-16	Selecky Christobel	director	Sale	50,000 @ $5.00	$250K	−100.0% of holding	+55.5%	+37.4%	0	Form 4 · filed 5 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

149 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-07-02	Cohen Cheryl	director	Option exercise	55,979	256,596	Form 4
2026-07-02	Cohen Cheryl	director	Option exercise	55,979	111,958	Form 4
2026-07-01	Selecky Christobel	director	Option exercise	124,414	159,478	Form 4
2026-07-01	Selecky Christobel	director	Option exercise	35,064	35,064	Form 4
2026-07-01	Selecky Christobel	director	Option exercise	35,064	0	Form 4
2026-07-01	Selecky Christobel	director	Option exercise	124,414	0	Form 4
2026-06-30	Selecky Christobel	director	Option exercise	700	700	Form 4
2026-06-30	Selecky Christobel	director	Option exercise	300	1,000	Form 4
2026-06-30	Selecky Christobel	director	Option exercise	700	35,064	Form 4
2026-06-30	Selecky Christobel	director	Option exercise	300	124,414	Form 4
2026-06-29	Selecky Christobel	director	Option exercise	33,549	65,722	Form 4
2026-06-29	Selecky Christobel	director	Option exercise	32,173	32,173	Form 4
2026-06-29	Selecky Christobel	director	Option exercise	30,000	95,722	Form 4
2026-06-29	Selecky Christobel	director	Option exercise	30,000	132,786	Form 4
2026-06-29	Selecky Christobel	director	Option exercise	33,549	124,714	Form 4
2026-06-29	Selecky Christobel	director	Option exercise	32,173	35,764	Form 4
2026-06-09	BLASZYK MICHAEL D	director	Award / grant	65,600	65,600	Form 4
2026-06-09	Clark Wesley	director	Award / grant	65,600	65,600	Form 4
2026-06-09	Cohen Cheryl	director	Award / grant	65,600	65,600	Form 4
2026-06-09	Wendel Bruce	director	Award / grant	65,600	65,600	Form 4
2026-06-09	MAXWELL LINDA	director	Award / grant	65,600	65,600	Form 4
2026-06-09	Selecky Christobel	director	Award / grant	65,600	65,600	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	4,606,596	251,018,873	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	—	—	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	—	—	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	—	—	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	—	—	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	—	—	Form 4
2026-03-31	SOON-SHIONG PATRICK	director	Conversion	—	—	Form 4
2026-02-23	Selecky Christobel	director	Option exercise	25,000	25,000	Form 4
2026-02-23	Selecky Christobel	director	Option exercise	25,000	67,937	Form 4
2026-02-22	Adcock Richard	director	Withheld for tax	77,560	560,344	Form 4
2026-02-22	SOON-SHIONG PATRICK	director	Withheld for tax	58,170	29,757,911	Form 4
2026-02-22	Sachs David C.	officer	Withheld for tax	20,682	300,143	Form 4
2026-02-22	Simon Barry J.	director	Withheld for tax	6,026	3,090,821	Form 4
2026-02-22	LAUER REGAN J	officer	Withheld for tax	1,673	115,875	Form 4
2026-02-22	Sachs David C.	officer	Option exercise	40,650	320,825	Form 4
2026-02-22	Sachs David C.	officer	Option exercise	40,650	40,651	Form 4
2026-02-22	Simon Barry J.	director	Option exercise	15,243	3,096,847	Form 4
2026-02-22	Simon Barry J.	director	Option exercise	15,243	15,245	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

27d remaining

2026-09-2610% elapsed2026-10-26

Logged immutably 2026-09-26; scored automatically on 2026-10-26 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Pending catalysts

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i